A big article talks about how some important medicine companies are in trouble because their special recipes (called patents) that make them lots of money will soon be used by other people. This means they need to find new ways to make money, and some of them are trying to help people with heart problems or sicknesses like cancer. Read from source...

- The title is misleading and clickbaity. A historical crossroads implies that the pharmaceutical industry is at a turning point or facing a major decision, but the article does not provide any evidence of such a situation. It only describes the challenges faced by some of the largest companies in the sector due to patent expirations and competition.
- The article uses vague terms like "patent cliffs" and "copycats" without explaining what they mean or how they affect the industry. This creates confusion and misinformation for the readers who are not familiar with the pharmaceutical terminology. A more accurate term would be "loss of exclusivity" which means that a company can no longer prevent other manufacturers from producing generic versions of its products without violating patent laws.
- The article mentions four companies: Bristol Myers Squibb, Merck & Co Inc, Pfizer Inc and Johnson & Johnson, but does not provide any comparative analysis or ranking of their performance, strategies, or outlooks. It also does not mention how these challenges affect other players in the industry, such as smaller biotech companies or generic drug makers. This creates an incomplete and unbalanced picture of the market situation.
- The article focuses on one deal that Johnson & Johnson signed with Shockwave Medical, but does not provide any details about the terms, size, or implications of this agreement. It also does not mention how this deal relates to the main topic of the article, which is the patent cliffs and the competitive pressure in the pharmaceutical industry. This creates a tangential and irrelevant sub-plot that distracts from the main message.